{"id":691111,"date":"2022-10-03T08:05:07","date_gmt":"2022-10-03T12:05:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\/"},"modified":"2022-10-03T08:05:07","modified_gmt":"2022-10-03T12:05:07","slug":"eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\/","title":{"rendered":"Eledon Pharmaceuticals to Participate in Two Upcoming Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">IRVINE, Calif., Oct.  03, 2022  (GLOBE NEWSWIRE) &#8212; Eledon Pharmaceuticals, Inc. (\u201cEledon\u201d) (NASDAQ: ELDN), today announced that senior management will participate in two upcoming conferences:<\/p>\n<ul type=\"disc\">\n<li>A panel discussion with Steven Perrin, Ph.D., President and Chief Scientific Officer, titled \u201cALS &#8212; New Treatment Paradigm with More MoAs on the Way?\u201d at the Cantor Neurology &amp; Psychiatry Conference on Thursday, October 6, 2022 at 1:20 p.m. ET; and\n<\/li>\n<li>An oral presentation by Jeff Bornstein, M.D., Chief Medical Officer, titled &#8220;Tegoprubart (AT-1501) is safe and well tolerated and reduces inflammation in patients with ALS\u201d at the ALS One 5<sup>th<\/sup> Annual ALS Research Symposium on Friday, October 7, 2022 at 11:40 a.m. ET.<\/li>\n<\/ul>\n<p>Both presentations will be available to registered conference attendees only. For additional information or to request a meeting with management, please contact conference representatives.<\/p>\n<p>\n        <strong>About Eledon Pharmaceuticals and tegoprubart (formerly AT-1501)<\/strong>\n      <\/p>\n<p>Eledon Pharmaceuticals\u00a0is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS. The company\u2019s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in\u00a0Irvine, Calif.\u00a0For more information, please visit the company\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xAG-vrAJjm3UbuGehMX5H7B3Arr-nQ6gsvovGlOOmq8QFyHs1MqbIpG0SwjDmnCA9Svu9l7nezzNsx9AfiXc3w==\" rel=\"nofollow noopener\" target=\"_blank\">www.eledon.com<\/a>.<\/p>\n<p>Follow Eledon Pharmaceuticals on social media: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gw0yR0DKGok6KZS6l6ttEuhLh6Lm8VAu0tqdwfr33MhwhdqioAq7CoAaG3N_wo1VHXXpS9QZf_JfvyKWMAV2pYp_5U74w5h2Y2G0sESZvuE=\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xL9wnNqnVnRAA59my56n0UKPmcxsuHuf1nMUzTKM1XtYai3xKHagOrB9YsAAtALPWvoz9Iu1JwwHj3FhrW8cCw==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a><\/p>\n<p>\n        <strong>Investor Contact:<\/strong>\n      <\/p>\n<p>Stephen Jasper<br \/>Gilmartin Group<br \/>(858) 525-2047<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4FYNa4Q50OzaeGdCtvLfmD9ukQao7oPGw_tWzXR4Bc9rvivHXyO5Iy_JYyC34KJaaaUjzZ_2N0BWlCEnh7hFmTDNvcYylWLGojFlLxCUchQ=\" rel=\"nofollow noopener\" target=\"_blank\">stephen@gilmartinir.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NzMzNCM1MTgzMDE5IzIwMDY1NTA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZTIzZjk3YTQtNDE3ZC00OTk0LWE0ZWItMmRhYzQ5NmViMmNhLTEwMTgxMjM=\/tiny\/Eledon-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>IRVINE, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) &#8212; Eledon Pharmaceuticals, Inc. (\u201cEledon\u201d) (NASDAQ: ELDN), today announced that senior management will participate in two upcoming conferences: A panel discussion with Steven Perrin, Ph.D., President and Chief Scientific Officer, titled \u201cALS &#8212; New Treatment Paradigm with More MoAs on the Way?\u201d at the Cantor Neurology &amp; Psychiatry Conference on Thursday, October 6, 2022 at 1:20 p.m. ET; and An oral presentation by Jeff Bornstein, M.D., Chief Medical Officer, titled &#8220;Tegoprubart (AT-1501) is safe and well tolerated and reduces inflammation in patients with ALS\u201d at the ALS One 5th Annual ALS Research Symposium on Friday, October 7, 2022 at 11:40 a.m. ET. Both presentations will be available to registered conference attendees only. For &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Eledon Pharmaceuticals to Participate in Two Upcoming Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-691111","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eledon Pharmaceuticals to Participate in Two Upcoming Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eledon Pharmaceuticals to Participate in Two Upcoming Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"IRVINE, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) &#8212; Eledon Pharmaceuticals, Inc. (\u201cEledon\u201d) (NASDAQ: ELDN), today announced that senior management will participate in two upcoming conferences: A panel discussion with Steven Perrin, Ph.D., President and Chief Scientific Officer, titled \u201cALS &#8212; New Treatment Paradigm with More MoAs on the Way?\u201d at the Cantor Neurology &amp; Psychiatry Conference on Thursday, October 6, 2022 at 1:20 p.m. ET; and An oral presentation by Jeff Bornstein, M.D., Chief Medical Officer, titled &#8220;Tegoprubart (AT-1501) is safe and well tolerated and reduces inflammation in patients with ALS\u201d at the ALS One 5th Annual ALS Research Symposium on Friday, October 7, 2022 at 11:40 a.m. ET. Both presentations will be available to registered conference attendees only. For &hellip; Continue reading &quot;Eledon Pharmaceuticals to Participate in Two Upcoming Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-03T12:05:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NzMzNCM1MTgzMDE5IzIwMDY1NTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Eledon Pharmaceuticals to Participate in Two Upcoming Conferences\",\"datePublished\":\"2022-10-03T12:05:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\\\/\"},\"wordCount\":249,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NzMzNCM1MTgzMDE5IzIwMDY1NTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\\\/\",\"name\":\"Eledon Pharmaceuticals to Participate in Two Upcoming Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NzMzNCM1MTgzMDE5IzIwMDY1NTA=\",\"datePublished\":\"2022-10-03T12:05:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NzMzNCM1MTgzMDE5IzIwMDY1NTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NzMzNCM1MTgzMDE5IzIwMDY1NTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eledon Pharmaceuticals to Participate in Two Upcoming Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eledon Pharmaceuticals to Participate in Two Upcoming Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Eledon Pharmaceuticals to Participate in Two Upcoming Conferences - Market Newsdesk","og_description":"IRVINE, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) &#8212; Eledon Pharmaceuticals, Inc. (\u201cEledon\u201d) (NASDAQ: ELDN), today announced that senior management will participate in two upcoming conferences: A panel discussion with Steven Perrin, Ph.D., President and Chief Scientific Officer, titled \u201cALS &#8212; New Treatment Paradigm with More MoAs on the Way?\u201d at the Cantor Neurology &amp; Psychiatry Conference on Thursday, October 6, 2022 at 1:20 p.m. ET; and An oral presentation by Jeff Bornstein, M.D., Chief Medical Officer, titled &#8220;Tegoprubart (AT-1501) is safe and well tolerated and reduces inflammation in patients with ALS\u201d at the ALS One 5th Annual ALS Research Symposium on Friday, October 7, 2022 at 11:40 a.m. ET. Both presentations will be available to registered conference attendees only. For &hellip; Continue reading \"Eledon Pharmaceuticals to Participate in Two Upcoming Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-03T12:05:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NzMzNCM1MTgzMDE5IzIwMDY1NTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Eledon Pharmaceuticals to Participate in Two Upcoming Conferences","datePublished":"2022-10-03T12:05:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\/"},"wordCount":249,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NzMzNCM1MTgzMDE5IzIwMDY1NTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\/","name":"Eledon Pharmaceuticals to Participate in Two Upcoming Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NzMzNCM1MTgzMDE5IzIwMDY1NTA=","datePublished":"2022-10-03T12:05:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NzMzNCM1MTgzMDE5IzIwMDY1NTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NzMzNCM1MTgzMDE5IzIwMDY1NTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-two-upcoming-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Eledon Pharmaceuticals to Participate in Two Upcoming Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/691111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=691111"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/691111\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=691111"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=691111"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=691111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}